 |
|
|
|
Ambler class |
Protein name |
PDB code |
Resolution (Å) |
Release date |
UniProt code |
PubMed ID |
DOI |
PDB |
Mutations |
Ligands |
Space group |
Unit cell parameters |
Z value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ||||||||
| C | FOX-4 | 5CGS | 1.63 | 2016-02-03 | Q9L387 | 26525784 | 10.1128/AAC.01887-15 | pdb | ZN | P 1 21 1 | 54.854 57.085 56.747 ♦ 90.00 96.45 90.00 | 2 | |
| C | FOX-4 | 5CGW | 1.40 | 2016-02-03 | Q9L387 | 26525784 | 10.1128/AAC.01887-15 | pdb | Y150F | ACT ZN | P 1 21 1 | 53.215 56.608 54.179 ♦ 90.00 96.24 90.00 | 2 |
| C | FOX-4 | 5CGX | 1.21 | 2016-02-03 | Q9L387 | 26525784 | 10.1128/AAC.01887-15 | pdb | Y150F | *1S7 NA ZN | P 1 21 1 | 54.524 56.588 55.485 ♦ 90.00 99.23 90.00 | 2 |
| C | FOX-4 | 5CHJ | 1.36 | 2016-08-03 | Q9L387 | 32349291 | 10.3390/biom10050671 | pdb | *SM2 ACT ZN | P 1 21 1 | 74.294 57.161 83.229 ♦ 90.00 91.67 90.00 | 4 | |
| C | FOX-4 | 5CHM | 1.90 | 2016-08-03 | Q9L387 | 32349291 | 10.3390/biom10050671 | pdb | *CB4 ACT NA ZN | P 1 21 1 | 54.803 57.144 56.123 ♦ 90.00 95.98 90.00 | 2 | |
| C | FOX-4 | 5CHU | 1.10 | 2016-08-03 | Q9L387 | pdb | ACT SO4 ZN | P 1 21 1 | 53.419 53.922 116.167 ♦ 90.00 89.87 90.00 | 4 | |||
| C | FOX-4 | 5ZA2 | 1.50 | 2018-03-07 | Q9L387 | 29439972 | 10.1128/AAC.02371-17 | pdb | *NXL EPE GOL SEP | P 21 21 21 | 51.391 85.908 144.227 ♦ 90.00 90.00 90.00 | 4 |
Statistics (number of structures): Overall (1663); class A (626); subclass B1 (403); subclass B2 (16); subclass B3 (104); class C (246); class D (268).
Last updated: January 08, 2024.
If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.
The development of the BLDB database is funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).
Contact: contact@bldb.eu